Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Integrated Human Evaluation of the Lysophosphatidic Acid Pathway as a Novel Therapeutic Target in Atherosclerosis

Variants in the PLPP3 gene encoding for lipid phosphate phosphohydrolase 3 have been associated with susceptibility to atherosclerosis independently of classical risk factors. PLPP3 inactivates lysophosphatidic acid (LPA), a pro-inflammatory, pro-thrombotic product of phospholipase activity. Here we...

Full description

Bibliographic Details
Main Authors: Silvia Aldi, Ljubica Perisic Matic, Gregory Hamm, Daniëlle van Keulen, Dennie Tempel, Kim Holmstrøm, Agnieszka Szwajda, Boye Schnack Nielsen, Valur Emilsson, Rima Ait-Belkacem, Mariette Lengquist, Gabrielle Paulsson-Berne, Per Eriksson, Jan H.N. Lindeman, Alain J. Gool, Jonathan Stauber, Ulf Hedin, Eva Hurt-Camejo
Format: Article
Language:English
Published: Elsevier 2018-09-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050118300494

Internet

http://www.sciencedirect.com/science/article/pii/S2329050118300494

Similar Items